Physician profile
Patrick Michael Dooley
NPI 1275571051
$4,058.53
in general payments reported to CMS, 2019-2025
9 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $264 · 2021: $1,288 · 2022: $617 · 2023: $521 · 2024: $448 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,394.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,324.91 | 2019-2025 | Acuvue |
| Coopervision INC. | $880.00 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $660.22 | 2022-2025 | Infuse, Biotrue, Infuse Svs |
| Alcon Vision LLC | $578.31 | 2019-2025 | Total30, Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $189.43 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $147.04 | 2022 | |
| Sun Pharmaceutical Industries INC. | $131.29 | 2021-2022 | |
| Biotissue Holdings INC. | $102.02 | 2020-2023 | |
| Oyster Point Pharma, INC. | $45.31 | 2022-2024 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Dooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.